Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

A Vaccine (DC/MM Fusion) in Combination with Elranatamab for the Treatment of Relapsed or Refractory Multiple Myeloma

Trial Status: active

This phase I trial tests the safety, side effects, and how well a vaccine (DC/MM fusion) in combination with elranatamab works in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). The DC/MM fusion vaccine tries to help the immune system recognize and fight against cancer cells. Unlike a standard vaccine that is used to prevent infections, cancer vaccines are being studied to see if they can fight cancers that are already in the body. This vaccine is individualized for each patient using dendritic cells (type of immune cells). Laboratory studies have shown that when dendritic cells and cancer cells are brought together, the dendritic cells can stimulate immune responses against the cancer and, in some cases, cause the cancer to shrink. Elranatamab is a type of immunotherapy that works by bringing healthy T cells (immune cells that help kill cancer cells) and myeloma cells close together so the T cells can more effectively kill the myeloma cells. Giving the DC/MM fusion vaccine in combination with elranatamab may be safe, tolerable and/or effective in treating patients with relapsed or refractory multiple myeloma.